Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:angiogenesis inhibitor
go back to main search page
Accession:CHEBI:48422 term browser browse the term
Definition:An agent and endogenous substances that antagonize or inhibit the development of new blood vessels.
Synonyms:related_synonym: angiogenesis antagonist;   angiostatic agents;   anti-angiogenic agent
 alt_id: CHEBI:67170
 xref: Wikipedia:Angiogenesis_inhibitor


show annotations for term's descendants           Sort by:
 
ageladine A term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CSNK1A1 casein kinase 1 alpha 1 decreases activity
affects activity
EXP Ageladine A analog results in decreased activity of CSNK1A1 protein
Ageladine A affects the activity of CSNK1A1 protein
CTD PMID:21413800 NCBI chr 2:150,612,845...150,662,431
Ensembl chr 2:150,612,844...150,662,351
JBrowse link
disulfiram term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2E1 cytochrome P450, family 2, subfamily E, polypeptide 1 multiple interactions EXP Disulfiram inhibits the reaction [4-xylene results in increased activity of CYP2E1 protein]; Disulfiram inhibits the reaction [Toluene results in increased activity of CYP2E1 protein] CTD PMID:12781212 NCBI chr14:141,690,737...141,703,078
Ensembl chr14:141,690,426...141,736,818
JBrowse link
G TNF tumor necrosis factor multiple interactions EXP Disulfiram inhibits the reaction [TNF protein results in increased abundance of Reactive Oxygen Species] CTD PMID:10975995 NCBI chr 7:23,699,635...23,702,393
Ensembl chr 7:23,699,636...23,703,655
JBrowse link
rifampicin term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G CYP2B22 cytochrome P450 2B22 increases expression EXP Rifampin results in increased expression of CYP2B22 mRNA CTD PMID:19464568 NCBI chr 6:49,158,175...49,173,872
Ensembl chr 6:49,110,812...49,178,413
JBrowse link
tamoxifen term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G ESR1 estrogen receptor 1 affects binding EXP Tamoxifen metabolite binds to ESR1 protein CTD PMID:16790557 NCBI chr 1:14,217,032...14,604,906
Ensembl chr 1:14,217,036...14,493,363
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 858
    role 836
      application 473
        pharmaceutical 418
          drug 418
            angiogenesis inhibitor 5
              (-)-antofine 0
              (-)-matairesinol + 0
              (-)-voacangine 0
              (1R,2S,3S,4S)-4-formyl-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexyl (2E)-3-(4-methoxyphenyl)acrylate 0
              (1S,2S,3S)-3-methoxy-2-[(2E)-6-methylhept-2-en-2-yl]-4-oxocyclohexanecarbaldehyde + 0
              (2S,3S,4S)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]-4-(trifluoroacetyl)cyclohexanone 0
              (2S,3S,4S)-4-(1,1,1,3,3,3-hexafluoro-2-hydroxypropan-2-yl)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (2S,3S,4S)-4-(hydroxymethyl)-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (2S,3S,4S)-4-acetyl-2-methoxy-3-[(2E)-6-methylhept-2-en-2-yl]cyclohexanone 0
              (4Z,7Z,10Z,12E,14S,16Z,19Z,21R)-dihydroxydocosahexaenoic acid 0
              3PO 0
              GP369 0
              JQ1 0
              N-(5-\{[(5-tert-butyl-1,3-oxazol-2-yl)methyl]sulfanyl\}-1,3-thiazol-2-yl)piperidine-4-carboxamide 0
              O-(chloroacetylcarbamoyl)fumagillol 0
              PD-166866 + 0
              SB220025 0
              SH-11037 0
              SU4312 0
              ageladine A 1
              amentoflavone + 0
              ascochlorin 0
              ascofuranone 0
              cafestol 0
              capsiate 0
              crenolanib 0
              disulfiram 2
              epoxytwinol A 0
              fumagillin + 0
              herbacetin 0
              kahweol 0
              lenalidomide 0
              leucosesterlactone 0
              leucosesterterpenone 0
              linifanib 0
              luminespib 0
              lupulone 0
              luteolin + 0
              meso-tetrakis(N-methyl-4-pyridyl)porphine tetrakis(p-toluenesulfonate) 0
              meso-tetrakis(N-methyl-4-pyridyl)porphine(4+) + 0
              nintedanib 0
              nintedanib esylate 0
              oridonin 0
              pomalidomide 0
              quininib 0
              quininib hydrochloride 0
              rifampicin + 1
              sorafenib + 0
              sunitinib + 0
              suramin 0
              tamoxifen + 1
              tamoxifen citrate 0
              thalidomide + 0
              toluquinol 0
              vatalanib + 0
              vatalanib succinate 0
              wogonin + 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.